Seattle Genetics is a biotechnology company that focuses on what is lacking in oncology. Many children and adults suffer from debilitating diseases that can be offset or avoided by stem cell research. A recent PRN News article has named Seattle Genetics as one of the fastest growing pharmaceutical companies in the industry. They understand there are a large number of people that have unmet medical needs. They are focused on the development and commercialization of microRNA (miRNA). They are the industry leaders in monoclonal antibodies and antibody-drug conjugates. Seattle Genetics continues to be a successful oncology provider and helping to heal thousands of people across the world annually.
Clay Siegall is the co-founder of Seattle Genetics and under his leadership they have become one of the most successful healthcare providers of antibody-drugs that are attacking agents that are killing the cells that lead to a lot of diseases and illnesses. Siegall has also helped earn a huge portion of financing to continue the valuable research into stem research. Building a successful oncology team increases the value of miRNA and micro-RNA based therapeutics. They also have a broad pipeline of other product brands that will treat illness and disease.
Seattle Genetics works closely with Takeda and has full commercialization rights to ADCETRIS. They put the needs of the patients first and want to provide a gateway for their patients that need oncology. Therapeutics is a safer method to cure or aid in many diseases that are affecting the daily lives of millions of people. They offer a wide program of services that will help you take back your life and get the productivity out of living everyday and being able to do the things that they use to or always wanted to do.
Micro-RNA are still in the early stages of research and Seattle Genetics with Clay Siegall depends on the generous donations of many people that make stem cell and oncology research possible. Their most popular feature is their clinical program that reduces the affects of the side affects of chemotherapy. You’re invited to visit their website for more details and information on their services and programs at Seattle Genetics.
Clay B. Siegall, Ph.D. is a co-founder, CEO and Chairman of Board of Directors of Seattle Genetics. In January 30, 2013, Clay was appointed to serve as an outside director to Mirna’s Board of Directors. Mirna Therapeutics is a biotechnology firm dealing with development and commercialization of mirna. Dr. Paul Lammers, President and CEO of Mirna, expressed his excitement for the inclusion of the new member. He said that the company was looking forward to benefiting from Siegall’s extensive experience in the pharmaceutical industry.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
miRNAs are global gene expression natural regulators encoded to the human genome. They are 20-25 nucleotides long and work by interacting with messenger RNAs. miRNAs regulate and coordinate several cellular processes and pathways since a single miRNA is able to regulate the expression of tens-hundreds of different genes. They also play several roles including facilitating proper embryonic development, cellular growth as well as proliferation, immunity and inflammation.
About Mirna Therapeutics
This is a biotechnological company founded in 2007. It is located in Austin, Texas. The pharmaceutical firm deals with development and commercialization of miRNAs, which are developed by in-house scientists and other in-licensed scientists from different institutions. Among the 300 miRNAs in its IP portfolio are key cancer tumor suppressors, miR-34 and let-7. These suppressors have proven to stop the growth of tumor in several animals. Mirna’s source of funds includes private investors, the State of Texas and the Research Institute of Texas. To view the original source of this information, go to the link below.
About Dr. Clay B. Siegall
In 1998, Dr. Siegall co-founded Seattle Genetics. Over the years, he has helped the company build a diverse channel of therapies based on antibody to deal with unattended needs of cancer patients. In August 2011, the company’s first commercial product, ADCETRIS® was approved. The entity has also collaborated with top biotechnology and pharmaceutical firms, earning over $675 million via public and private funding. Clay is an active member of the Board of Directors for Alder Biopharmaceuticals. Previously, he worked for Bristol-Myers Squibb Pharmaceutical Research Institute and National Cancer Institutes of Health. The author of over 70 publications went to George Washington University and the University of Maryland where he earned his PhD in Genetics and received a B.S. in zoology respectively.
Seattle Genetics is a multimillion dollar company cofounded by Dr. Clay Siegall in 1998. The company primarily focuses on the synthesis and application of antibody-drug conjugates (ADCs), which are used in new, targeted therapies against cancer. The therapies work by combining an anti-body with high specificity, will only latch on to one target, with a drug connected by a linking molecule that will be stable within the bloodstream, but will break down upon entering a cancerous cell. Seattle Genetics’ ADCETRIS® (brentuximab vedotin) is the first cancer therapy to be approved by the FDA using this system and has already been used to treat more than 15,000 lymphoma patients. Aside from this, the company is working on a variety of different treatments using their trademarked system in hopes to find treatments for a variety of different cancers and treat a wide scope of patients.
Dr. Siegall received his B.S. in Zoology from the University of Maryland and his Ph.D. in genetics from University of Washington. Dr. Siegall has had numerous ties with big name health and pharmaceutical institutes, having worked with the National Cancer Institute and National Institute of Health for three years, 1988-1991, followed by the Bristol-Myers Squibb Pharmaceutical research institute for six years, 1991-1997. Dr. Siegall is on the board of directors for several companies including Ultragenyx and Mirna Therapeutics and has many collaborations with Genentech, MedImmune, and Bayer and Progenics. Dr. Siegall’s active career has afforded him authorship of more than 70 publications and currently holds fifteen patents, which is a fairly remarkable number is the scientific world.
Dr. Siegall continues to work as the president of Seattle Genetics maintaining its position as one of the world’s leader in antibody research and is attempting to branch out further into autoimmune treatments for use in cancer treatment. He is currently most excited about developing a new treatment for acute myeloid leukemia, which will selectively attack targets found ubiquitously in leukemia cells. The company hopes to perfect its method of treatments allowing for the selective attack on cancer cells, while sparing healthy cells.
Learn More about Clay: